Rare Disease Editorial Staff

The drug is approved as a treatment for adult patients with newly-diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

Moxetumomab pasudotox (Lumoxiti, AstraZeneca)is approved for adults with relapsed or refractory HCL who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog.